Tredje AP fonden Sells 444 Shares of Catalent, Inc. (NYSE:CTLT)

Tredje AP fonden lowered its stake in shares of Catalent, Inc. (NYSE:CTLT) by 1.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,401 shares of the company’s stock after selling 444 shares during the period. Tredje AP fonden’s holdings in Catalent were worth $1,597,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Lindbrook Capital LLC lifted its position in shares of Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent in the 2nd quarter worth approximately $42,000. Mather Group LLC. purchased a new stake in shares of Catalent during the 1st quarter worth approximately $52,000. Longfellow Investment Management Co. LLC boosted its position in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares during the last quarter. Finally, Principal Securities Inc. purchased a new position in shares of Catalent in the fourth quarter valued at $56,000.

Analysts Set New Price Targets

CTLT has been the topic of a number of recent research reports. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, July 11th. StockNews.com initiated coverage on Catalent in a research report on Wednesday. They issued a “sell” rating for the company. Finally, Barclays increased their price target on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $58.08.

Catalent Stock Down 0.2 %

NYSE:CTLT opened at $60.00 on Friday. The company’s 50-day simple moving average is $59.48 and its 200-day simple moving average is $57.21. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.77 and a current ratio of 2.52. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $61.20. The stock has a market capitalization of $10.86 billion, a P/E ratio of -9.84, a P/E/G ratio of 1.88 and a beta of 1.15.

Insider Activity at Catalent

In other Catalent news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares in the company, valued at $1,785,251.44. The disclosure for this sale can be found here. Insiders sold 13,409 shares of company stock valued at $782,923 over the last 90 days. Insiders own 0.31% of the company’s stock.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.